Insmed Inc INSM
We take great care to ensure that the data presented and summarized in this overview for INSMED Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INSM
View all-
Vanguard Group Inc Valley Forge, PA14.5MShares$799 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$650 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$593 Million0.04% of portfolio
-
State Street Corp Boston, MA5.91MShares$325 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.78MShares$263 Million4.29% of portfolio
-
Palo Alto Investors LP Palo Alto, CA4.42MShares$244 Million14.02% of portfolio
-
William Blair Investment Management, LLC Chicago, IL4.21MShares$232 Million0.31% of portfolio
-
Macquarie Group LTD Australia, C33.9MShares$215 Million0.12% of portfolio
-
Pictet Asset Management Sa Geneva 73, V83.7MShares$203 Million0.09% of portfolio
-
Franklin Resources Inc San Mateo, CA3.57MShares$196 Million0.03% of portfolio
Latest Institutional Activity in INSM
Top Purchases
Top Sells
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Transactions at INSM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 30
2024
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,195
-16.65%
|
$1,165,725
$55.0 P/Share
|
|
May 30
2024
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,195
+14.27%
|
$487,485
$23.75 P/Share
|
|
May 29
2024
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
220,564
-65.25%
|
$11,028,200
$50.0 P/Share
|
|
May 29
2024
|
Sara Bonstein Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
220,564
+12.2%
|
$5,734,664
$26.26 P/Share
|
|
May 28
2024
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
44,722
-33.49%
|
$2,191,378
$49.53 P/Share
|
|
May 28
2024
|
Michael Alexander Smith Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,971
+6.12%
|
$506,623
$13.63 P/Share
|
|
May 28
2024
|
John Drayton Wise Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,852
-3.09%
|
$384,748
$49.48 P/Share
|
|
May 28
2024
|
John Drayton Wise Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+4.66%
|
$75,000
$12.58 P/Share
|
|
May 28
2024
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,724
-5.78%
|
$1,036,200
$50.01 P/Share
|
|
May 28
2024
|
Sara Bonstein Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,724
+1.57%
|
$538,824
$26.26 P/Share
|
|
May 28
2024
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
103,806
-49.45%
|
$5,086,494
$49.62 P/Share
|
|
May 28
2024
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
103,806
+33.09%
|
$2,387,538
$23.66 P/Share
|
|
May 28
2024
|
Orlov S Nicole Schaeffer Chief People Strategy Officer |
SELL
Open market or private sale
|
Direct |
27,500
-20.18%
|
$1,347,500
$49.53 P/Share
|
|
May 28
2024
|
Orlov S Nicole Schaeffer Chief People Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+16.79%
|
$330,000
$12.58 P/Share
|
|
May 17
2024
|
Roger Adsett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,945
-3.83%
|
$148,625
$25.09 P/Share
|
|
May 17
2024
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,642
-4.19%
|
$116,050
$25.09 P/Share
|
|
May 14
2024
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,093
-5.11%
|
$127,325
$25.4 P/Share
|
|
May 14
2024
|
John Drayton Wise Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,088
-3.96%
|
$127,200
$25.47 P/Share
|
|
May 14
2024
|
Roger Adsett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,857
-4.82%
|
$196,425
$25.5 P/Share
|
|
May 14
2024
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,088
-8.62%
|
$277,200
$25.32 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 346K shares |
|---|---|
| Exercise of conversion of derivative security | 718K shares |
| Bona fide gift | 3.6K shares |
| Open market or private sale | 845K shares |
|---|---|
| Bona fide gift | 3.6K shares |